Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431952 | 0.89 | HTR6 (0.53) | HTR6CCR1 | |
| SCHEMBL5421824 | 0.84 | HTR6 (0.44) | HTR6EPHX2TP53TDP1TSHR | |
| SCHEMBL5430660 | 0.84 | HTR6 (0.49) | HTR6EPHX2TDP1LMNAALDH1A1 | |
| SCHEMBL5423536 | 0.83 | MBTD1 (0.54) | HTR6TP53MAPTTDP1TSHR | |
| SCHEMBL3144812 | 0.82 | HTR6 (0.77) | HTR6CCR1EPHX2 | |
| SCHEMBL5427892 | 0.81 | HTR6 (0.45) | HTR6CCR1MAPTTDP1TSHR | |
| SCHEMBL5428073 | 0.81 | EPHX2 (0.43) | HTR6CCR1EPHX2TP53MAPT | |
| SCHEMBL5439699 | 0.80 | ALDH1A1 (0.55) | HTR6TP53MAPTTDP1TSHR | |
| SCHEMBL5430905 | 0.80 | PKM (0.50) | HTR6CCR1TP53TDP1TSHR | |
| SCHEMBL5781991 | 0.79 | SMN1; SMN2 (0.50) | HTR6TP53MAPTTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | HTR6 1/4885CCR1 4779/4885EPHX2 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.